Abstract

AbstractThe rarity of WM limits the ability to perform large randomized clinical trials comparing treatment regimens. Prospective single-arm studies, however, have led to the development of effective therapies. The choice of treatment should consider patient-specific characteristics and anticipated toxicities, as well as patient and provider preference. Additionally, MYD88 and CXCR4 mutations are known to affect treatment response and progression-free survival (PFS).

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call